TBPH Theravance Biopharma (TBPH) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001583107
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
101
13F, latest reported quarter
What the filings say about TBPH
Insiders, 180 days
-$6.4M net sold
2 sellers · 27% of sales under a 10b5-1 plan
Congress, 1 year
No trades
Last one: sale, 2025-03-24
Planned sales (Form 144), 90 days
$226.8K
1 notice
Theravance Biopharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Theravance Biopharma, Inc. insiders sold a net $6.4M of stock across 56 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Jun 15, 2026.
- The trade is 1.5% of the 223,461 shares held after it.
- No other insider sold within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold about $56.7K of TBPH under a 10b5-1 plan on Sep 15, 2026; 101 funds added in the latest 13F quarter.Context
- 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Jun 15, 2026.
- The trade is 1.5% of the 220,133 shares held after it.
- No other insider sold within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold about $56.7K of TBPH under a 10b5-1 plan on Sep 15, 2026; 101 funds added in the latest 13F quarter.Context
- 24 earlier Form 4 trades (code P or S) here by this insider (24 sales), the last on Jun 15, 2026.
- The trade is 3.1% of the 213,476 shares held after it.
- No other insider sold within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold about $113.4K of TBPH under a 10b5-1 plan on Sep 15, 2026; 101 funds added in the latest 13F quarter.Context
- 7 earlier Form 4 trades (code P or S) here by this insider (3 buys, 4 sales), the last on Jul 6, 2026.
- +9.7% median (+9.7% mean) 90-day return after 2 previous buys.
- The trade is 0.1% of the 9,167,489 shares held after it.
- 1 other insider sold within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Samaha Eli sold about $95.5K of TBPH on Jul 7, 2026; 1 other insider sold within 30 days and 101 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (3 buys, 3 sales), the last on Jul 1, 2026.
- +9.7% median (+9.7% mean) 90-day return after 2 previous buys.
- The trade is 0.0% of the 9,173,053 shares held after it.
- 1 other insider sold within 30 days.
- 101 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Samaha Eli sold about $23.9K of TBPH on Jul 6, 2026; 1 other insider sold within 30 days and 101 funds added in the latest 13F quarter.56 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$6.4M over 180 days
-$226.8K over 90 days · -$5.9M of it by a 10%+ holder
below 81% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
101 funds bought in last quarter
more than 68% of Pharma & Biotech
Revenue
+66.9% year over year
more than 82% of Pharma & Biotech
Margin
98.5% net margin
more than 97% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
no short interest reported
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch TBPH
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+20.4%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns TBPH: institutional holders (13F)
13F holdings, latest reported quarter
9,212,252 sh
$156.6M
7,457,060 sh
$126.8M
4,562,487 sh
$77.6M
3,434,191 sh
$58.4M
2,760,948 sh
$46.9M
Congress trades in TBPH
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-03-24 · disclosed 30 days later
$15,001 - $50,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
TBPH planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
RHONDA FARNUM
Filed 2026-09-15
$226.8K
TBPH mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
PROFUND VP PHARMACEUTICALS
$106.9K position · as of 2026-06-30
0.9%
JAMES MICRO CAP FUND
$244.2K position · as of 2026-06-30
0.7%
Direxion Daily Pharmaceutical & Medical Bull 3X Shares
$146.1K position · as of 2026-07-31
0.7%
ALPS Medical Breakthroughs ETF
$838.8K position · as of 2026-05-31
0.5%
iShares US Small Cap Value Factor ETF
$773.5K position · as of 2026-06-30
0.4%
Invesco NASDAQ Future Gen 200 ETF
$67.6K position · as of 2026-05-31
0.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
4 registered trials, 1 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 2
0 active
2
Phase 3
1 active
1
Phase 4
0 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Rick Winningham
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2022
$6.3M
$6.7M
$971.4K
-57%
+11%
2021
$4.5M
$1.9M
$2.8M
-57%
+25%
2020
$6.6M
$1.8M
$2.7M
-31%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $6.4M sold by insiders over 180 days, 101 funds added last quarter, $226.8K in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
TBPH financials
Revenue growth
+66.9%
XBRL, annual
Net margin
98.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$104.3M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM TBPH
| FY Dec 2025 | $107.5M |
| FY Dec 2024 | $64.4M |
| FY Dec 2023 | $57.4M |
| FY Dec 2022 | $51.3M |
| FY Dec 2021 | $55.3M |
| Jun 2026 | $20.7M |
| Mar 2026 | $17.7M |
| Dec 2025 | $45.9M |
| Sep 2025 | $20.0M |
| Jun 2025 | $26.2M |
| Mar 2025 | $15.4M |
| Dec 2024 | $18.8M |
| Sep 2024 | $16.9M |
At each fiscal year end
Single quarter
Net margin, TTM
+51.6%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM TBPH
| FY Dec 2025 | +98.5% |
| FY Dec 2024 | -87.6% |
| FY Dec 2023 | -96.1% |
| FY Dec 2022 | +1,699% |
| FY Dec 2021 | -360.6% |
| Jun 2026 | -28.5% |
| Mar 2026 | -27.9% |
| Dec 2025 | +133.0% |
| Sep 2025 | +18.1% |
| Jun 2025 | +209.3% |
| Mar 2025 | -88.2% |
| Dec 2024 | -82.8% |
| Sep 2024 | -75.3% |
At each fiscal year end
Single quarter
Free cash flow, TTM
n/a
capex not filed for the four quarters
Free cash flow, TTM TBPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | -$11.9M |
| FY Dec 2023 | -$29.5M |
| FY Dec 2022 | -$187.6M |
| FY Dec 2021 | -$211.3M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | -$6.1M |
| Sep 2025 | -$6.5M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -$1.1M |
| Sep 2024 | -$5.2M |
At each fiscal year end
Single quarter
Debt to equity
0.00x
long-term debt only, 2023-12-31 (30 months older than the period end); equity 2026-06-30
Debt to equity TBPH
| FY Dec 2025 | 0.00x |
| FY Dec 2024 | 0.00x |
| FY Dec 2023 | 0.00x |
| FY Dec 2022 | 1.41x |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.00x |
| Mar 2026 | 0.00x |
| Dec 2025 | 0.00x |
| Sep 2025 | 0.00x |
| Jun 2025 | 0.00x |
| Mar 2025 | 0.00x |
| Dec 2024 | 0.00x |
| Sep 2024 | 0.00x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt to cover
Cash flow to debt TBPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | -0.30x |
| FY Dec 2021 | -0.34x |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+20.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity TBPH
| FY Dec 2025 | +44.8% |
| FY Dec 2024 | -29.0% |
| FY Dec 2023 | -16.9% |
| FY Dec 2022 | +1,690% |
| FY Dec 2021 | n/a |
| Jun 2026 | +20.9% |
| Mar 2026 | +50.2% |
| Dec 2025 | +44.8% |
| Sep 2025 | +14.0% |
| Jun 2025 | +6.2% |
| Mar 2025 | -31.5% |
| Dec 2024 | -29.0% |
| Sep 2024 | -22.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+12.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets TBPH
| FY Dec 2025 | +25.2% |
| FY Dec 2024 | -15.3% |
| FY Dec 2023 | -11.2% |
| FY Dec 2022 | +177.6% |
| FY Dec 2021 | -47.3% |
| Jun 2026 | +12.0% |
| Mar 2026 | +28.1% |
| Dec 2025 | +25.2% |
| Sep 2025 | +7.6% |
| Jun 2025 | +3.3% |
| Mar 2025 | -16.3% |
| Dec 2024 | -15.3% |
| Sep 2024 | -12.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
-59.7%
operating income after a 8.7% effective tax rate, over long-term debt only, 2023-12-31 (30 months older than the period end) plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital TBPH
| FY Dec 2025 | -2.2% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | -59.7% |
| Mar 2026 | +3.9% |
| Dec 2025 | -2.2% |
| Sep 2025 | -18.5% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-1.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed TBPH
| FY Dec 2025 | -0.9% |
| FY Dec 2024 | -13.8% |
| FY Dec 2023 | -12.0% |
| FY Dec 2022 | -20.6% |
| FY Dec 2021 | -77.9% |
| Jun 2026 | -1.0% |
| Mar 2026 | +0.4% |
| Dec 2025 | -0.9% |
| Sep 2025 | -9.2% |
| Jun 2025 | -10.5% |
| Mar 2025 | -15.2% |
| Dec 2024 | -13.8% |
| Sep 2024 | -12.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
16.86x
close 2026-09-25 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing TBPH
| FY Dec 2025 | 9.22x |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | 0.97x |
| FY Dec 2021 | n/a |
| Jun 2026 | 16.83x |
| Mar 2026 | 7.38x |
| Dec 2025 | 9.22x |
| Sep 2025 | 25.61x |
| Jun 2025 | 45.96x |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$664.4M
market value at close 2026-09-25 on 2026-07-31 shares, plus long-term debt only, 2023-12-31 (30 months older than the period end), minus cash 2026-06-30
Enterprise value TBPH
| FY Dec 2025 | $780.3M |
| FY Dec 2024 | $424.9M |
| FY Dec 2023 | $520.2M |
| FY Dec 2022 | $1.1B |
| FY Dec 2021 | $1.3B |
| Jun 2026 | $656.6M |
| Mar 2026 | $547.6M |
| Dec 2025 | $780.3M |
| Sep 2025 | $560.5M |
| Jun 2025 | $269.6M |
| Mar 2025 | $331.2M |
| Dec 2024 | $424.9M |
| Sep 2024 | $370.9M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
n/a
capex not filed for the four quarters
FCF yield TBPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | -2.6% |
| FY Dec 2023 | -5.3% |
| FY Dec 2022 | -24.8% |
| FY Dec 2021 | -25.9% |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | +44.4% |
| Mar 2025 | +7.3% |
| Dec 2024 | -2.6% |
| Sep 2024 | -3.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.05x
P/E over trailing EPS growth of 321%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing TBPH
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.05x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-09-25. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $107.5M | $64.4M | $57.4M | $51.3M |
| Operating income | -$3.6M | -$46.9M | -$56.0M | -$92.0M |
| Net income | $105.9M | -$56.4M | -$55.2M | $872.1M |
| EPS (diluted) | 2.06 | -1.15 | -1.00 | 11.85 |
| Operating cash flow | $238.5M | -$11.5M | -$27.0M | -$187.0M |
| Cash | $167.8M | $37.8M | $39.5M | $298.2M |
| Long-term debt | n/a | n/a | $0 | n/a |
| Buybacks | n/a | $445.0K | $197.1M | $128.8M |
SEC XBRL, fiscal years, as known on 2026-10-28
TBPH Stock Sonar score 6/7 axes
Find similar shapesCompareTBPH ranks highest on financial health (99th percentile) and growth (82nd), and lowest on insider conviction (9th), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
TBPH filings, in plain words
Are Theravance Biopharma insiders buying or selling TBPH?
In the 180 days to 2026-10-28, Theravance Biopharma insiders were net sellers, a net $6.4M across purchases and sales reported on Form 4, by 2 sellers.
Have members of Congress traded TBPH?
Yes, but not in the year to 2026-10-28; the latest on record is a sale by George Whitesides dated 2025-03-24.
Are there planned insider sales of TBPH?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $226.8K of stock; the latest, by RHONDA FARNUM, was filed 2026-09-15.
Read the full summary
In the 180 days to 2026-10-28, Theravance Biopharma insiders were net sellers of TBPH, a net $6.4M across purchases and sales reported on Form 4 by 2 sellers. Most of that figure, $5.9M, came from a holder of 10% or more rather than an officer or director. 27% of the 11 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Members of Congress have disclosed trades in TBPH, none in the last year; the latest on record is a sale by George Whitesides dated 2025-03-24. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $226.8K of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
